2021 BRN Discussion, page-33321

Thanks Esq,

That report was very helpful in building my confidence on Brainchip. Being listed at no. 2 by Deloitte was comforting that the small numbers company had done their research and thought so highly of them. Unfortunately for me I didn’t see the report when it first came out and my buy in price was much higher.

At the time of writing the report Covid wasn’t a thing: so I’m not sure the author would have been aware of the Nanose device which will hopefully become commercialized in 2022. That may affect the SP SLIGHTLY!

The long list of possible EAP’s, the fantastic team, and plethora of uses help consolidate my desire to become involved in this great company.

I’m still buying. Now that Xmas has passed and I financially survived without any bill shocks I bought some more this morning, luckily in the first 30 seconds of trade or I’d still be in the queue.

All my opinion of course and DYO: Bring on an explosive 2022!